(Total Views: 440)
Posted On: 10/07/2019 3:33:29 PM
Post# of 70
NetworkNewsBreaks – Neutra Corp. (NTRR) Subsidiary Nearing Market Release of Hemp-Based Sports Cream Expected to be Hit with Amateur and Pro Athletes
Early-stage research and development company Neutra Corp. (OTCQB: NTRR) today announced that its subsidiary VIVIS Corp. is rapidly approaching the market release of a new transdermal, hemp-based sports cream. According to the update, the company believes the new product will prove popular with amateur athletes and others seeking relief after tough workouts and performances. The announcement is the latest in Neutra’s series of bold initiatives that it undertook earlier this year to grab a share of a market analysts predict will hit $11 billion by 2026. “We’re now seeing the positive payoff of hiring a dedicated sports medicine advisor earlier this year,” Neutra’s CEO Sydney Jim said in the news release. “Our goal with that hire was to develop hemp-based CBD (cannabidiol) products geared to the expanding sports market. VIVIS’ upcoming transdermal sports cream will appeal to the rapidly growing number of active Americans wanting to improve performance, relieve aches and pains, prevent injuries and lead healthier lifestyles. And as with all VIVIS products, this sports cream will be third-party verified for consistency, potency and as contaminant-free.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Early-stage research and development company Neutra Corp. (OTCQB: NTRR) today announced that its subsidiary VIVIS Corp. is rapidly approaching the market release of a new transdermal, hemp-based sports cream. According to the update, the company believes the new product will prove popular with amateur athletes and others seeking relief after tough workouts and performances. The announcement is the latest in Neutra’s series of bold initiatives that it undertook earlier this year to grab a share of a market analysts predict will hit $11 billion by 2026. “We’re now seeing the positive payoff of hiring a dedicated sports medicine advisor earlier this year,” Neutra’s CEO Sydney Jim said in the news release. “Our goal with that hire was to develop hemp-based CBD (cannabidiol) products geared to the expanding sports market. VIVIS’ upcoming transdermal sports cream will appeal to the rapidly growing number of active Americans wanting to improve performance, relieve aches and pains, prevent injuries and lead healthier lifestyles. And as with all VIVIS products, this sports cream will be third-party verified for consistency, potency and as contaminant-free.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
